An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma
NCT06668792
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG:
BCD-248
Sponsor
Biocad